It’s far better to be alone than to be in bad company

由 Duruisseaux, Michael, Cadranel, Jacques
發表在 J Thorac Dis (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

由 Denis, Morgane, Duruisseaux, Michael, Brevet, Marie, Dumontet, Charles
發表在 Front Immunol (2020)

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma

由 Duruisseaux, Michaël, Rabbe, Nathalie, Antoine, Martine, Vieira, Thibault, Poulot, Virginie, Cadranel, Jacques, Wislez, Marie
發表在 ERJ Open Res (2017)

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma

由 Duruisseaux, Michaël, McLeer‐Florin, Anne, Antoine, Martine, Alavizadeh, Sanaz, Poulot, Virginie, Lacave, Roger, Rabbe, Nathalie, Cadranel, Jacques, Wislez, Marie
發表在 Cancer Med (2016)

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

由 Rozensztajn, Nathalie, Ruppert, Anne-Marie, Lavole, Armelle, Leprieur, Etienne Giroux, Duruisseaux, Michael, Vieira, Thibault, Rabbe, Nathalie, Lacave, Roger, Antoine, Martine, Cadranel, Jacques, Wislez, Marie
出版 2014

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

由 de la Bruyère, Charline Lafayolle, Souquet, Pierre-Jean, Dalle, Stéphane, Corbaux, Pauline, Boespflug, Amélie, Duruisseaux, Michaël, Kiakouama-Maleka, Lize, Reverdy, Thibaut, Maugeais, Madeleine, Sahin, Gulsum, Maillet, Denis, Péron, Julien
發表在 Cancers (Basel) (2021)

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

由 Hervé, Virginie, Rabbe, Nathalie, Guilleminault, Laurent, Paul, Flora, Schlick, Laurène, Azzopardi, Nicolas, Duruisseaux, Michael, Fouquenet, Delphine, Montharu, Jérôme, Redini, Françoise, Paintaud, Gilles, Lemarié, Etienne, Cadranel, Jacques, Wislez, Marie, Heuzé-Vourc’h, Nathalie
發表在 MAbs (2014)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

由 Gounant, Valérie, Duruisseaux, Michael, Soussi, Ghassen, Van Hulst, Sylvie, Bylicki, Olivier, Cadranel, Jacques, Wislez, Marie, Trédaniel, Jean, Spano, Jean-Philippe, Helissey, Carole, Chouaid, Christos, Molinier, Olivier, Dhalluin, Xavier, Doucet, Ludovic, Hureaux, José, Cazes, Aurélie, Zalcman, Gérard
發表在 Cancers (Basel) (2021)

Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

由 Cadranel, Jacques, Liu, Stephen V., Duruisseaux, Michaël, Branden, Eva, Goto, Yasushi, Weinberg, Benjamin A., Heining, Christoph, Schlenk, Richard F., Cheema, Parneet, Jones, Martin R., Drilon, Alexander, Trombetta, Domenico, Muscarella, Lucia Anna, Tolba, Khaled, Gounant, Valerie, Cseh, Agnieszka, Solca, Flavio, Laskin, Janessa J., Renouf, Daniel J.
發表在 Oncologist (2020)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

由 Duruisseaux, Michaël, Besse, Benjamin, Cadranel, Jacques, Pérol, Maurice, Mennecier, Bertrand, Bigay-Game, Laurence, Descourt, Renaud, Dansin, Eric, Audigier-Valette, Clarisse, Moreau, Lionel, Hureaux, José, Veillon, Remi, Otto, Josiane, Madroszyk-Flandin, Anne, Cortot, Alexis, Guichard, François, Boudou-Rouquette, Pascaline, Langlais, Alexandra, Missy, Pascale, Morin, Franck, Moro-Sibilot, Denis
發表在 Oncotarget (2017)

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

由 Gadgeel, Shirish M., Shaw, Alice T., Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A., Camidge, D. Ross, De Petris, Luigi, Kim, Dong-Wan, Chiappori, Alberto, Moro-Sibilot, Denis L., Duruisseaux, Michael, Crino, Lucio, De Pas, Tommaso, Dansin, Eric, Tessmer, Antje, Yang, James Chih-Hsin, Han, Ji-Youn, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Ou, Sai-Hong Ignatius
發表在 J Clin Oncol (2016)

Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: A Series of 49 Patients and Review of the Literature

由 Comarmond, Cloé, Crestani, Bruno, Tazi, Abdellatif, Hervier, Baptiste, Adam-Marchand, Sylvain, Nunes, Hilario, Cohen-Aubart, Fleur, Wislez, Marie, Cadranel, Jacques, Housset, Bruno, Lloret-Linares, Célia, Sève, Pascal, Pagnoux, Christian, Abad, Sébastien, Camuset, Juliette, Bienvenu, Boris, Duruisseaux, Michaël, Hachulla, Eric, Arlet, Jean-Benoît, Hamidou, Mohammed, Mahr, Alfred, Resche-Rigon, Matthieu, Brun, Anne-Laure, Grenier, Philippe, Cacoub, Patrice, Saadoun, David
發表在 Medicine (Baltimore) (2014)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

由 Illini, Oliver, Hochmair, Maximilian Johannes, Fabikan, Hannah, Weinlinger, Christoph, Tufman, Amanda, Swalduz, Aurélie, Lamberg, Kristina, Hashemi, Sayed M. S., Huemer, Florian, Vikström, Anders, Wermke, Martin, Absenger, Gudrun, Addeo, Alfredo, Banerji, Shantanu, Calles, Antonio, Clarke, Stephen, Di Maio, Massimo, Durand, Alice, Duruisseaux, Michaël, Itchins, Malinda, Kääränien, Okko-Sakari, Krenn, Florian, Laack, Eckart, de Langen, Adrianus Johannes, Mohorcic, Katja, Pall, Georg, Passaro, Antonio, Prager, Gerald, Rittmeyer, Achim, Rothenstein, Jeffrey, Schumacher, Michael, Wöll, Ewald, Valipour, Arschang
發表在 Ther Adv Med Oncol (2021)